News & Views - Page 32 of 53 - Telix Pharmaceuticals Limited

Telix Further Strengthens European Distribution Network for Illuccix

Telix announces agreements with Avanço and THP for the distribution of Telix’s prostate cancer investigational imaging product for the Portuguese and Austrian, Czech Republic and Slovak Republic markets.

Activities Report and Appendix 4C for March 2022 Quarter

Telix issues Appendix 4C quarterly cash flow statement and accompanying Activities Report for the quarter ended 31 March 2022

First Patients Dosed with Illuccix® – Telix’s Approved Prostate Cancer Imaging Agent

Telix announces the first commercial doses of its prostate cancer imaging agent, Illuccix® 

Notice of Annual General Meeting 2022

Telix provides notice of The Annual General Meeting of Shareholders on Wednesday 18 May 2022

ProstACT Update: TARGET Study Ethics Approval

Telix’s ProstACT TARGET Phase II clinical trial of prostate cancer antibody therapy candidate TLX591 has been granted Human Research Ethics Committee approval.

Telix Announces Licence Agreement with Lilly for Olaratumab

Telix announces a licence agreement for Lilly’s olaratumab antibody, for diagnosis and treatment of human cancers.

PSMA-PET Imaging to be Funded through Medicare in Australia from July

Telix welcomes the listing of prostate-specific membrane antigen (PSMA) positron emission tomography (PET) (PSMA-PET) imaging for patients with prostate cancer on the Medicare Benefits Schedule (MBS) from 1 July 2022.

Telix, GMS and Monash Awarded $23M Federal Government Funding as part of $71M Australian Precision Medicine Enterprise (APME) Project

Telix announces that it is part of a $71.2 million Australian Precision Medicine Enterprise Project, which has been awarded $23 million in Federal Government funding

Commercial Launch: Illuccix® Now Available to Order in the United States

Telix announces that its prostate cancer imaging agent, Illuccix® (kit for preparation of gallium Ga 68 gozetotide), also known as 68Ga-PSMA-11 injection, is now commercially available in the United States.

2nd Joint Telix and Duchembio Symposium – Clinical Utility of PSMA PET Imaging in Prostate Cancer and Key PSMA PET Image Interpretation for Urologists

On World Theranostics Day, with our partner, Duchembio, we are pleased to present the 2nd joint symposium on the clinical utility of PSMA-PET in prostate cancer imaging and key PSMA PET image interpretation for urologists in Korea.